

Ctexli

Abu Dhabi · access guide

How to access Ctexli for cerebrotendinous xanthomatosis from Abu Dhabi: 2026 pathway via SSMC, CCAD, Tawam, and SKMC metabolic-genetics | Reserve Meds

By Reserve Meds clinical & regulatory team. Last reviewed 2026-05-20.

Abu Dhabi holds the UAE's strongest in-emirate metabolic-genetics and adult-neurology depth at SSMC, CCAD, Tawam Hospital, SKMC, and Burjeel Medical City. CTX cases identified within Abu Dhabi are confirmed in-emirate and managed in-emirate. The 2026 question is how to source Ctexli, the first FDA-approved oral chenodeoxycholic acid replacement therapy for CTX.

Why Ctexli, why now

Ctexli received FDA approval in February 2024 as the first labelled treatment for CTX, paediatric and adult. CTX is recessive bile-acid synthesis disorder driven by CYP27A1 mutations, with progressive neurologic deterioration, tendon xanthomas, juvenile cataracts, and early atherosclerosis if untreated. With FDA approval less than 24 months ago, the Abu Dhabi pathway is named-patient import under EDE.

What Ctexli is, in plain language

Ctexli is oral chenodiol capsules. It replaces the bile acid the patient's enzyme cannot make and restores feedback suppression of cholestanol. It does not reverse damage. It slows or halts progression and lowers cholestanol. Weight-based dosing, three times daily with food, lifelong.

Eligibility at an Abu Dhabi metabolic-genetics or neurology clinic

Required: biallelic CYP27A1 pathogenic variants on genetics, plus elevated plasma cholestanol. CCAD genetic disease programme, SSMC metabolic clinic, Tawam paediatric and adult neurology, and SKMC paediatric neurology each handle confirmation and management.

The Abu Dhabi prescribing and supply picture

Ctexli is not EDE-registered as of 2026. Access is via EDE-approved named-patient import filed through SSMC, CCAD, Tawam, or SKMC pharmacy with DoH Abu Dhabi acknowledgment. Reserve Meds coordinates the import file, prescription chain, and temperature-controlled US or EU sourcing.

Cost band

USD 150K-220K annual per patient (AED 550K-810K), weight-dependent, lifelong. Thiqa coverage path for Emirati nationals under rare-disease provision case-by-case; Daman Enhanced and private payors require pre-authorisation with genetics and treating-specialist letter.

What to expect, week-by-week

Weeks 0 to 4: confirm diagnosis, prescription, EDE import filing through Abu Dhabi pharmacy. Weeks 4 to 8: shipment arrives, initiation under metabolic-genetics or neurology supervision, baseline labs documented. Weeks 8 to 24: cholestanol trend, liver function, tolerability monitored. Month 6 and 12: full metabolic and neurologic reassessment and MRI white-matter.

When Ctexli is the wrong drug

No biallelic CYP27A1 means not this drug. Normal cholestanol means diagnosis in doubt. Advanced neurologic damage means stabilisation goal; family counselling required. Pregnancy data limited; contraception required for women of childbearing age.

Closing

Reserve Meds runs the Ctexli import file from the Abu Dhabi metabolic-genetics or neurology referral through EDE named-patient authorisation, US or EU sourcing, and delivered emirate supply. Clinical decisions remain with your treating metabolic specialist or neurologist.

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

Reserve Meds

reserved for you.

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemed.com · hello@reservemed.com